What is Deepcure?
Deepcure is at the forefront of pharmaceutical innovation, leveraging an advanced AI-driven drug discovery platform coupled with an automated robotic laboratory. This unique combination allows the company to accelerate the development of novel therapeutics, positioning it as a key player in the biotech sector. The company's approach aims to streamline the traditionally lengthy and costly process of bringing new drugs to market.
How much funding has Deepcure raised?
Deepcure has raised a total of $104M across 2 funding rounds:
Series A
$40M
Series A
$64M
Series A (2021): $40M with participation from Benon Group, The Morningside Group, TLV Partners, and Sapir Venture Partners
Series A (2024): $64M led by The Morningside Group, Benon Group, IAG Capital Partners, and Sapir Venture Partners
Key Investors in Deepcure
The Morningside Group
Morningside Group is a Hong Kong-based private equity and venture capital firm founded in 1986, known for its investments in early-stage companies and its commitment to social responsibility.
Sapir Venture Partners
Sapir Venture Partners focuses on empowering entrepreneurs by providing resources and support to foster innovation and growth in various sectors, catering to startups and emerging businesses.
IAG Capital Partners
IAG Capital Partners is a venture capital firm specializing in leading investment rounds from seed to Series C, operating from Charleston, SC, and London, UK, to support innovative companies.
What's next for Deepcure?
The substantial enterprise-level funding, particularly the recent strategic investment, signals a pivotal growth phase for Deepcure. This capital infusion is expected to fuel further development of its AI platform, expand its laboratory capabilities, and potentially accelerate clinical trials. The company is poised to make significant advancements in drug development, building on its technological foundation and strategic financial backing.
See full Deepcure company page
